2Giles F,Verstovsek S,Garcia-Manero G,et al.Validation of the European Prognostic Index for young adult patients with acute myeloid leukemia in first relapse[J].Br J Haematol,2006,134(1):58-60.
3Perrot A,Luquet I,Pigneux A,et al.Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia:a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities[J].Blood,2011,118(3):679-685.
4Chevallier P,Labopin M,Turlure P,et al.A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukaemia patients:a GOELAMS study[J].Leukemia,2011,25(6):939-944.
5Scappini B,Gianfaldoni G,Caracciolo F,et al.Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients[J].Am J Hematol,2012,87(12):1047-1051.
6Faderl S,Wetzler M.Rizzieri D,et al.Clofarabine plus cytarabine compared with eytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia:results from the CLASSIC I Trial[J].J Clin Oncol,2012,30(20):2492-2499.
7Roboz GJ,Giles FJ,Ritchie EK,et al.Phase Ⅰ / Ⅱ study of continuous infusion troxacitabine in refractory acute myeloid leukemia[J].J Clin Oncol,2007,25 (1):10-15.
8Kantarjian H,Garcia-Manero G,O' Brien S,et al.Phase Ⅰ clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome[J].J Clin Oncol,2010,28(2):285-291.
9Fenaux P,Mufti GJ,Hellstrom-Lindberg E,et al.Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia[J].J Clin Oncol,2010,28 (4):562-569.
10Platzbecker U,Wermke M,Radke J,et al.Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneie HSCT:results of the RELAZA trial[J].Leukemia,2012,26(3):381-389.
